Publication
Ready, set, grow (and SELL)! Spotlight on industrial hemp
Author:
Global | Publication | August 2018
The Cannabis Act and its regulations are delivering big for Canada’s industrial hemp industry: the much-desired and long-awaited right to sell the whole industrial hemp plant.
The Controlled Drugs and Substances Act currently regulates the cultivation and sale of industrial hemp in Canada.. Under this regime, only certain parts of the industrial hemp plant (the stems and stalks) can be sold.
Further to our previous update, the new Industrial Hemp Regulations made under the Cannabis Act (the 2018 IHR) have been published. These will replace the existing Industrial Hemp Regulations made under the Controlled Drugs and Substances Act. Effective October 17, 2018, the 2018 IHR will regulate the cultivation, sale, import and export of industrial hemp in Canada.
Similar to the existing Industrial Hemp Regulations, the 2018 IHR are largely devoted to licensing and post-licensing requirements, with some changes to reduce the regulatory burden on the industry to better reflect the low-risk nature of industrial hemp and the longstanding experience of both Health Canada and the industry of growing industrial hemp in a controlled fashion.
Among the biggest news coming out of the new regime for regulating cannabis is industrial hemp farmers’ new ability to sell the whole plant, including the cannabinoid-rich leaves, flowering heads and branches to other federal license holders.
It should come as no surprise that many industry watchdogs are putting a spotlight on industrial hemp, particularly given that the plant is rich in cannabidiol (CBD), one of the most highly sought-after phytocannabinoids. We are watching with great interest as this Canadian industry continues to develop.
Recent publications
Publication
The GCR Guide to Life Sciences – Product denigration
Marta Giner Asins and Arnaud Sanz of our Paris office are the authors of a chapter on product denigration that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences.
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .